In both chambers of Congress, passing legislation to bring down drug prices is a policy priority—and the savings from such possible legislation is slated to offset other healthcare legislative proposals (such as addressing impending Medicaid Disproportionate Share Hospital (DSH) allotment ...
In the first three years of life, a child’s brain is developing at an unparalleled pace.
On June 24, 2019, President Donald Trump issued an “Executive Order on Improving Price and Quality Transparency in American Healthcare to Put Patients First.”
The pediatric channel provides a unique opportunity to reach parents and their children during the first three years of life.
Any time a company is engaged in content marketing—whether it is creating content itself or acting through influencers—it is important to be cognizant of intellectual property (IP) issues.
On July 9, Judge Amit P. Mehta of the U.S. District Court, District of Columbia vacated an administration final rule that would have required drug manufacturers to disclose wholesale acquisition prices in their television broadcast advertising.
Before addressing legal requirements and compliance practices, it is important to understand the terminology used in discussing prize promotions.
Dual eligibles—those eligible for both Medicare and Medicaid—are among the most costly and complex enrollees in both programs.
High out-of-pocket costs can be a significant barrier to access for Part D enrollees, especially for non-low-income subsidy (LIS) enrollees with a condition that requires an expensive specialty drug for treatment.
On May 31, 2019, Utah released a draft Section 1115 waiver application, the Per Capita Cap Demonstration, for public comment.